Foodie Pundit

Federal Health Plans Confront a Multibillion-Dollar Weight-Loss Drug Dilemma

As millions of federal workers gain access to GLP-1 medications like Ozempic and Wegovy, the government health system faces a major test of budgets and benefits.

By Foodie Pundit Newsroom - Published - Updated - Section: Glp1 Weight Loss

Federal Health Plans Confront a Multibillion-Dollar Weight-Loss Drug Dilemma

Key points

  • The U.S. Office of Personnel Management (OPM) has directed all Federal Employees Health Benefits (FEHB) carriers to cover anti-obesity medications, granting access to GLP-1 drugs for approximately 8 million federal workers and their families.
  • While a major win for health advocates, the high cost of drugs like Wegovy (over $1,300/month list price) poses a significant financial challenge, with potential expenditures reaching billions and threatening premium hikes for all members.
  • Insurers are using strategies like strict prior authorization and tiered formularies to manage costs, requiring patients to meet specific BMI and health criteria before getting a prescription approved.
  • Recent studies showing that GLP-1 drugs can significantly reduce cardiovascular events like heart attacks and strokes bolster the argument that their high cost is a worthwhile long-term investment in public health, potentially offsetting future medical expenses.
  • The federal government's experience will be a critical test case for how large employer health systems can balance the immense health potential of these drugs against their immediate and substantial budgetary impact.

This report is part of Foodie Pundit premium coverage. Foodie Pundit members read the full story. See membership.

Sources and methodology

Reported from the public datasets below.

All sources Foodie Pundit reports from

More from the Foodie Pundit Newsroom

Permalink